Form 4 for ARTV Artiva Biotherapeutics, Inc.
Accepted 2025-04-25 00:00:00 ET · period of report 2025-04-08 · accession 0001415889-25-011379 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-04-25 | 2025-04-08 | ARTV | Banerjee Subhashis | Chief Medical Off | A - Grant | $0.00 | +50.0K | 50.0K | New | $0 |
| D | 2025-04-25 | 2025-04-08 | ARTV | Banerjee Subhashis | Chief Medical Off | A - Grant | $0.00 | +80.0K | 80.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-08 | A | A | 50,000 | $0.00 | 50,000 | D | — | — | (F1) Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. |
| 2 | Derivative | Employee Stock Option (Right to Buy) | 2025-04-08 | A | A | 80,000 | $0.00 | 80,000 | D | $1.92 · — to 2035-04-07 | 80,000 Common Stock | (F2) 25% of the shares initially subject to the option will vest and become exercisable on April 8, 2026, and the balance of the shares subject to the option shall vest and become exercisable at a rate of 1/36th per month over the following 36 months. |